First Republic Investment Management Inc. raised its holdings in Mylan (NASDAQ:MYL) by 12.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,505 shares of the company’s stock after buying an additional 2,845 shares during the quarter. First Republic Investment Management Inc.’s holdings in Mylan were worth $832,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of the business. Meeder Asset Management Inc. grew its holdings in shares of Mylan by 76.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock worth $106,000 after purchasing an additional 1,475 shares during the period. BT Investment Management Ltd purchased a new stake in shares of Mylan during the 3rd quarter worth about $142,000. Global X Management Co. LLC grew its holdings in shares of Mylan by 59.2% during the 2nd quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock worth $186,000 after purchasing an additional 1,786 shares during the period. Doliver Capital Advisors LP purchased a new stake in shares of Mylan during the 2nd quarter worth about $201,000. Finally, Sheaff Brock Investment Advisors LLC purchased a new stake in shares of Mylan during the 2nd quarter worth about $210,000. Institutional investors own 75.04% of the company’s stock.
MYL has been the subject of a number of research reports. Wells Fargo & Company set a $32.00 target price on Mylan and gave the stock a “hold” rating in a report on Wednesday, October 4th. Morgan Stanley boosted their target price on Mylan from $36.00 to $39.00 and gave the stock an “equal weight” rating in a report on Friday, October 6th. BidaskClub upgraded Mylan from a “hold” rating to a “buy” rating in a report on Friday, October 27th. BMO Capital Markets reiterated a “buy” rating and set a $45.00 target price on shares of Mylan in a report on Friday, September 29th. Finally, ValuEngine upgraded Mylan from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $42.41.
Mylan (NASDAQ:MYL) opened at $40.01 on Friday. The company has a market capitalization of $21,210.00, a P/E ratio of 8.36, a P/E/G ratio of 2.15 and a beta of 1.38. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. Mylan has a 52-week low of $29.39 and a 52-week high of $45.87.
Mylan (NASDAQ:MYL) last released its quarterly earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.10). The company had revenue of $2.99 billion for the quarter, compared to analyst estimates of $3.09 billion. Mylan had a return on equity of 20.63% and a net margin of 7.28%. The business’s revenue was down 2.3% on a year-over-year basis. During the same period last year, the firm posted $1.38 earnings per share. analysts predict that Mylan will post 4.56 earnings per share for the current fiscal year.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.